Could Drug-Resistant Bacteria Cause The Next Pandemic?

As humanity tallies the growing cost of Covid-19 in lives and capital, it must address the Grey Rhino threats posed by pathogenic bacteria. These are probable and impactful, but we neglect them despite their obviousness. Aided by modern humans’ mobility and by climate change, bacterial pathogens endanger everyone’s health. They are legion, varied, and constantly mutating. How can we best combat them?

Click HERE to read the article on Forbes.

WHO warns overuse of antibiotics for Covid-19 will cause more deaths

The increased use of antibiotics to combat the Covid-19 pandemic will strengthen bacterial resistance and ultimately lead to more deaths during the crisis and beyond, the World Health Organization (WHO) has warned. WHO director general Tedros Adhanom Ghebreyesus said on Monday that a “worrying number” of bacterial infections were becoming increasingly resistant to the medicines traditionally used to treat them.

Click HERE to read the article on The Guardian.

Path To Profitability

According to the industry analysts covering BOT, breakeven is near. They anticipate the company to incur a final loss in 2021, before generating positive profits of AU$33m in 2022. Therefore, BOT is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, I calculated the rate at which BOT must grow year-on-year. It turns out an average annual growth rate of 96% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Click HERE to read the article on Simply Wall Street.

Is Cannabis Space Offering a Lucrative Investment Opportunity Amid Coronavirus Outbreak?

The legal cannabis market in Australia is set to boom, and cannabis is turning out to be the one thing that wouldn’t be hampered by seasonality. The country has one of the largest medicinal cannabis markets that is regulated by the federal government. The cannabis industry is one of the most disputed sectors throughout the world, and over the past few months, significant development has been observed in the industry.

Click HERE to read the article on Kalkine Media.

Botanix Pharmaceuticals receives FDA grant for antibacterial product BTX 1801

Amid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast track its first antibacterial product BTX 1801.

Earlier today, the company announced that the FDA’s Office of Antimicrobial Products had granted BTX 1801 – a treatment to prevent post-surgical infections – what’s known as qualified infectious disease product (QIDP) status which means Botanix can receive a variety of incentives as part of its drug development program.

Click HERE to read the article on SmallCaps.

Botanix reshuffles business priorities

Botanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.

Click HERE to read the article on The Green Fund.

Botanix signs a supply agreement with Purisys

Botanix Pharmaceuticals has entered into a supply agreement with Purisys. Purisys has one of the industry’s longest track records and a wide range of offerings in the cannabinoid space. It currently produces all major cannabinoids relevant to pharmaceutical and consumer products. Since 2016, Purisys has also manufactured pharmaceutical-grade cannabidiol at commercial scale utilising a patented process.

Click HERE to read the article on The Market Herald.

Pharma giants to unveil major $1 billion venture to push novel antibiotics

Amid escalating concerns over antibiotic resistance, several big drug makers are creating a new $1 billion for-profit venture to acquire or invest in small antibiotic companies and their nascent products, according to two people familiar with the plans.

Click HERE to see the article on STAT.

Prepare for Lift-off – Botanix raises $40 million and strengthens leadership team

Botanix Pharmaceuticals Limited (ASX:BOT)—a clinical stage cannabinoid company—has received firm commitments for a $40 million placement led by specialist US-based biotech investment funds and leading US institutional investors.

The $40 million in funding—which was offered at a price of $0.21 per fully paid ordinary share—will be used to support the company’s cannabinoid clinical development and research portfolio.

Click HERE to read the article on The Green Fund.

Could CBD Fight Superbugs? Marijuana Compound Shows Promise As an Antibiotic.

The quest for new antibiotics has led researchers to a surprising candidate: the marijuana compound CBD.

A new study finds that CBD, or cannabidiol, is “remarkably effective” at killing bacteria, at least in a test tube, the researchers in the new study said. The results showed that CBD had antibiotic effects against a number of so-called Gram-positive bacteria, including types of staph and strep bacteria, as well as strains that had become resistant to other antibiotic drugs.

Click HERE to read the article on LiveScience.